Company Overview and News

Cervantes Corporation directors complete field visit to Primrose Project

Cervantes Corporation Ltd (ASX:CVS) has sent two directors to complete a field visit at its Primrose Project within the Paynes Find Goldfield in Western Australia.

Cervantes Corporation pursues strategy for near-term, cheap gold production

Cervantes Corporation Limited (ASX:CVS) has exited a minerals sands project and is continuing to pursue “fast wins” in the gold sector as it focuses on projects with the potential for cheap, near-term production.

Cervantes Corporation focused on gold projects after discussions with Baraka

Cervantes Corporation Ltd (ASX:CVS) believes the recent exploration success at its Albury Heath gold project will help it repay a two year $900,000 interest-free loan early.

Cervantes Corporation’s Pansy Pit in WA may have more gold to give

Cervantes Corporation Ltd (ASX:CVS) has intercepted shallow high-grade gold mineralisation in the historical Pansy Pit at its Primrose Gold Project in Western Australia.

Cervantes Corporation intersects high-grade gold at Albury Heath project

Cervantes Corporation Ltd (ASX:CVS) has hit significant gold intersections in a drilling program at its Albury Heath Gold Project in Western Australia.

Cervantes looking for fast turnaround gold projects in established mining regions

2018-07-16 - 1
Cervantes Corp (ASX:CVS) managing director Marcus Flis speaks with Proactive Investors about how the company is looking to prove itself in the market.

European Lithium banks on gold upside of Cervantes as it lifts stake to 8%

European Lithium Ltd (ASX:EUR) (FRA:PF8) (VSE:ELI) is banking on the gold strategy of Cervantes Corporation Limited (ASX:CVS) by securing an 8% stake in the explorer.

Cervantes Corporation surges 143% on bonanza-grade gold results from Albury Heath

Cervantes Corporation Limited (ASX:CVS) surged 143% in early trade after receiving a number of bonanza-grade gold intersections from the Albury Heath project in Western Australia.

European Lithium updates on sale of non-core project, PFS expected this week

European Lithium Ltd (ASX:EUR) has divested its Paynes Find Gold Project in Western Australia to Cervantes Corporation Ltd (ASX:CVS).

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CVS / CERVANTES CORPORATION LIMITED on message board site Silicon Investor.

cvs cvs cvs CVSN: ChromaVision Medical Sys. CVSN: ChromaVision Medical Sys. CVSN: ChromaVision Medical Sys.
ChromaVision Med. Sys. (CVSN) ChromaVision Med. Sys. (CVSN) ChromaVision Med. Sys. (CVSN) CVS Corp CVS Corp CVS Corp